MARS Bioimaging Closes $15M Series A Funding

Why It Matters

The infusion positions MARS to scale a novel, contrast‑free CT platform that could disrupt conventional imaging workflows and expand access in cost‑sensitive markets. Accelerated adoption may reshape diagnostic radiology and spur new contrast‑agent research.

Key Takeaways

• $15M Series A led by Pacific Channel.
• Funding split: $7.6M initial, $7.4M later.
• Funds target US, NZ, India market expansion.
• Portable spectral CT provides contrast‑free, 3‑D imaging.
• Built on CERN Medipix technology for material differentiation.

Pulse Analysis

The medical imaging sector is witnessing a shift toward spectral photon‑counting computed tomography, a technology that captures energy‑resolved X‑ray data to differentiate materials within a single scan. MARS Bioimaging’s portable scanner leverages this principle, delivering three‑dimensional colour images that distinguish bone, soft tissue, blood vessels and metallic implants without injecting contrast agents. By eliminating contrast‑related risks and reducing procedure time, the system addresses a long‑standing bottleneck in orthopaedic diagnostics and research on novel contrast media. Its compact form factor also opens possibilities for point‑of‑care deployment in hospitals and field clinics.

The $15 million Series A, split into a $7.6 million initial close and a $7.4 million follow‑on, reflects growing investor confidence in high‑resolution, low‑dose imaging solutions. Led by Pacific Channel, the round brings strategic expertise in scaling life‑science ventures across the Asia‑Pacific and North American markets. MARS plans to channel the capital into regulatory approvals, manufacturing capacity, and sales teams targeting the United States, New Zealand and high‑growth regions such as India. This infusion not only accelerates the company’s go‑to‑market timeline but also highlights New Zealand’s emerging role as a hub for med‑tech innovation.

Industry analysts see contrast‑free photon‑counting CT as a potential game‑changer for radiology, offering superior tissue characterization while lowering patient exposure. If MARS can achieve widespread clinical adoption, it could pressure incumbent CT manufacturers to integrate spectral capabilities or risk losing market share. Moreover, the technology’s ability to visualize material composition may spur new applications in drug development, implant monitoring, and personalized medicine. As hospitals seek cost‑effective, versatile imaging platforms, MARS Bioimaging’s funding milestone positions it to influence the next generation of diagnostic equipment.